JPH08512046A - 抗アテローム性動脈硬化症ジアリール化合物 - Google Patents
抗アテローム性動脈硬化症ジアリール化合物Info
- Publication number
- JPH08512046A JPH08512046A JP7503357A JP50335795A JPH08512046A JP H08512046 A JPH08512046 A JP H08512046A JP 7503357 A JP7503357 A JP 7503357A JP 50335795 A JP50335795 A JP 50335795A JP H08512046 A JPH08512046 A JP H08512046A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- phenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
- C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 医学的治療に用いるための式(I)の化合物又はその薬学的に許容され る塩、溶媒和物、もしくは生理学的に機能性のある誘導体。 (上記式中、 Wは水素、又は、ハロ、C1ー4アルキル、C1ー4アルコキシ、ヒドロキシ、C1ー 4 ハロアルキル、C1ー4ハロアルコキシ及びRC(O)−(ここでRは、水素、C1ー4 アルキル、C1ー4アルコキシ、ヒドロキシ、C1ー4ハロアルキル、及びC1ー4ハ ロアルコキシから選ばれる)から独立して選ばれる1個以上の基で置換されてい てもよいC1-12ヒドロカルビル基であり、 Xは−NR1C(O)NR2−、−NR1C(O)−、−NR1C(O)O−、− C(O)NR2−、又は−OC(O)NR2−(ここでR1及びR2は、水素、C1- 4 アルキル、及びC1ー4ハロアルキルから独立して選ばれる)であり、 Yは結合、C2ー4アルキニレン、C2ー4アルケニレン(シスもしくはトランス) 、C1-4アルキレン、−(CH2)n−O−(CH2)p−、又は−(CH2)n−S (O)q−(CH2)p−(ここでnとpは0、1、2、3及び4から独立して選 ばれる整数であるが、但し、n+pは4より大きくなく、またqは0、1及び2 から選ばれる整数である)であり、またYは、ハロ、C1-4アルキル、及びC1-4 ハロアルキルから独立して選ばれる1個以上の基により置換されていてもよく、 Eは結合、C1ー4アルキレン、−(CH2)r−O−(CH2)s−、−(C H2)r−S(O)t−(CH2)s−、−(CH2)r−C(O)−(CH2)s−( ここでr及びsは0、1、2、3及び4から抽立して選ばれる整数であるが、但 し、r+sは4より大きくなく、またtは0、1及び2から選ばれる整数である )、−OC(O)−、−C(O)O−、−S(O)2N(R3)−、−(R3)N S(O)2−、−C(O)N(R3)−、−(R3)NC(O)N(R4)−、又は −(R3)NC(O)−(ここでR3とR4は、水素、C1-4アルキル、及びC1-4 ハロアルキルから独立して選ばれる)であり、 Zは脂肪族環系、C1-8アルキル、C1-8アルコキシ、ヒドロキシ、ハロ、又は アリールであり、またZは、ハロ、シアノ、−CO2R6、−C(O)NR6R7、 −NR6R7(ここでR6及びR7は、水素、C1-4アルキル、及びC1-4ハロアルキ ルから独立して選ばれる)、C1ー4アルキル、C1-4ハロアルキル、C1-4アルコ キシ、C1-4ハロアルコキシ、ヒドロキシ、及びC2-8ポリエーテルから独立して 選ばれる1個以上の基により置換されていてもよく、 フェニル環A及びBは、ハロ、C1-4アルキル、C1-4ハロアルキル、C1-4ア ルコキシ、C1-4ハロアルコキシ、ヒドロキシ、シアノ、R8R9NC(O)−、R8 C(O)N(R9)−、R8C(O)O−、及びR8C(O)−(ここでR8及び R9は、水素、C1-4アルキル、及びC1-4ハロアルキルから独立して選ばれる) から独立して選ばれる1個以上の基により置換されていてもよく、 但し、Yがメチレン、エチレンもしくはn−プロピレン、又は−CH=CH− (シスもしくはトランス)である場合には、−E−Z基は、独立して選ばれた1 個以上の極性基により置換されていてもよいC1ー6アルキルではない) 2. 治療上の有効量の式(I)の化合物(請求項1で定義した通り)、又は その薬学的に許容される塩、溶媒和物、もしくは生理学的に機能性のある誘導体 を哺乳類に投与することからなる、ACAT抑制剤が必要とされるヒトのような 哺乳類における臨床的症状の予防もしくは治療方法。 3. 以下の条件を満たす、請求項1で定義した式(I)の化合物、又はその 塩、溶媒和物、もしくは生理学的に機能性のある誘導体。 (i)Yが−S−であり、Xが−NR1C(O)−(ここでR1は、水素もしく はC1ー3アルキルである)であり、そしてWが水素もしくはC1ー3アルキルである 場合に、−E−Zがメトキシではない。 (ii)Yが−S−又は−O−であり、Xが−C(O)NH−であり、Wが水 素であり、環Aが未置換であるか、又はC1ー4アルキルもしくはC1-4アルコキシ から選ばれる置換基を1個有し、そして環Bが未置換であるか、又はハロゲン及 びアルキルから選ばれる置換基を1個〜3個有する場合に、−E−Zが、置換さ れていてもよいシクロアルキル、ハロゲン又はアルキルメルカプトではない。 (iii)式(I)の化合物が、 N,N−ジエチル−2〔2−(4−メトキシフェニル)エテニル〕ベンズアミ ド、 ビス〔2−(N−イソプロピルカルバモイル)フェニル〕スルフィド、 ビス〔2−(N−イソプロピルカルバモイル)フェニル〕スルホキシド、 ビス〔2−(N−イソプロピルカルバモイル)フェニル〕スルホン、 2,2’−チオビス〔N,N−ビス(1−メチルプロピル)ベンズアミド〕、 又は 2,2’−チオビス(N−ブチルベンズアミド) ではない。 4. Wが請求項1に記載のように置換されていてもよいC3-7アルキルであ り、 Xが−C(O)NR2−、−NR1C(O)−、又は−NR1C(O)NR2−( ここでR1及びR2は請求項1で定義した通りである)であり、 Yがエチレン、エテニレン、エチニレン、−O−、−S−、−CH2O−、又 は−OCH2−であり、 Eが−O−、−OCH2−、−CH2O−、結合、−C(O)N(R3)−、− (R3)NC(O)−、−S−、−S(O)−、−S(O)2−、−(R3)NS (O)2−、−S(O)2N(R3)−、−(R3)NC(O)N(R4)−、又は −C(O)−(ここでR3及びR4は請求項1で定義した通りである)であり、そ して Zが−N(R5)−(ここでR5は、水素、C1ー4アルキル、及びC1ー4ハロアル キルから選ばれる)、−C(O)−、及び−O−から選ばれる基を1個、2個、 もしくは3個含んでいてもよい飽和5員環もしくは6員環であるか、又はZがC1ー4 アルキル、C1ー4アルコキシ、ヒドロキシもしくはアリールであって、またZ が請求項1に記載のように置換されていてもよい、 請求項3に記載の式(I)の化合物、又はその塩、溶媒和物、もしくは生理学的 に機能性のある誘導体。 5. WがC3-5アルキルであり、 Xが−C(O)NH−であり、 Yがエチニレン、又は−O−であり、 Eが−O−、又は結合であり、 Zが−N(R5)−(ここでR5は、水素、C1ー4アルキル、及びC1ー4ハロアル キルから選ばれる)、−C(O)−、及び−O−から選ばれる基を1個、2個、 もしくは3個含んでいてもよい飽和5員環もしくは6員環であるか、又はZがC1ー4 アルキルもしくはC1-4アルコキシであって、またZが請求項1で記載のよう に置換されていてもよく、そして −E−Z基が、Y基に関してパラ位で環Bと結合している、 請求項3もしくは4に記載の式(I)の化合物、又はその塩、溶媒和物、もしく は生理学的に機能性のある誘導体。 6. N−{2,4−ジフルオロ−6−〔4−(1−カルバモイル−1−メチ ルエチル)フェノキシ〕フェニル}ピバルアミド、 N−{2,4−ジフルオロ−6−〔4−(2,6−ジオキソ−4−ピペリジニ ル)フェニルエチニル〕フェニル}ピバルアミド、 N−〔2−フルオロ−6−(4−トリフルオロメトキシフェノキシ)フェニル 〕ピバルアミド、 N−{2,4−ジフルオロ−6−〔4−(4−メトキシテトラヒドロピラン− 4−イル)フェニルエチニル〕フェニル}ピバルアミド、 N−{2,4−ジフルオロ−6−〔4−(2,6−ジオキソ−4−ピペリジニ ル)フェノキシ〕フェニル}ピバルアミド、 N−{6−〔4−(1−カルバモイル−1−メチルエトキシ)フェニルエチニ ル〕−2,4−ジフルオロフェニル}ピバルアミド、 N−{6−〔4−(1−カルバモイル−1−メチルエチル)フェニルエチニル 〕−2,4−ジフルオロフェニル}ピバルアミド、 1−〔4−(3−フルオロ−2−ピバルアミドフェノキシ)フェニル〕シクロ ペンタン−1−カルボン酸、及び 1−〔4−(3−フルオロ−2−ピバルアミドフェノキシ)フェニル〕シクロ ペンタン−1−カルボキサミドから選ばれる請求項3〜5のいずれか1項に記載 の式(I)の化合物、又はその塩、溶媒和物、もしくは生理学的に機能性のある 誘導体。 7. ACAT抑制剤が必要とされる臨床的症状の予防又は治療用の薬剤の製 造における、式(I)の化合物(請求項1で定義した通り)、又はその薬学的に 許容される塩、溶媒和物、もしくは生理学的に機能性のある誘導体の使用。 8. 式(I)の化合物(請求項1で定義した通り)、又はその薬学的に許容 される塩、溶媒和物、もしくは生理学的に機能性のある誘導体と、薬学的に許容 されるキャリアーもしくは賦形剤とからなる医薬組成物。 9. 式(II)の化合物と式(III)の化合物 (上記式中、 Y’とY”は、一緒に反応して所望の結合Y(式(I)で定義した通り)を形 成することのできる基であり、 (WX)’−は、W−X−基(ここでWとXは式(I)で定義した通りである )、その保護された形態、又は該W−X−基の前駆体のいずれかであり、 −(EZ)’は、−E−Z基(ここでEとZは式(I)で定義した通りである )、その保護された形態、又は該−E−Z基の前駆体のいずれかであり、 また環A及びBは、式(I)で述べたように置換されていてもよい) とをカップリングして式(I)の化合物、又は式(IV)の化合物 (上記式中、Yは式(I)で定義した通りであり、(WX)’−と−(EZ)’ はそれぞれ式(II)と式(III)で定義した通りであり(式(I)の化合物 となる(WX)’−と−(EZ)’との組み合わせは除く)、また環A及びBは 、式(I)で述べたように置換されていてもよい) を得、その後、 (i)式(II)の化合物において(WX)’−がW−X−基の前駆体である 場合にはW−X−基を形成し、及び/又は (ii)式(III)の化合物において−(EZ)’が−E−Z基の前駆体で ある場合には−E−Z基を形成し、及び/又は (iii)あらゆる保護基を除去し、及び/又は (iv)任意の工程として、以下で述べるような、得られる式(I)の化合物 の塩、溶媒和物、もしくは生理学的に機能性のある誘導体を形成し、又は式(I )の別の化合物へ転化する ことからなる、請求項3〜5のいずれか一項に記載の式(I)の化合物、又はそ の塩、溶媒和物、もしくは生理学的に機能性のある誘導体の製造法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939313459A GB9313459D0 (en) | 1993-06-30 | 1993-06-30 | Diaryl compounds |
GB9313459-1 | 1993-06-30 | ||
GB9406005A GB9406005D0 (en) | 1994-03-25 | 1994-03-25 | Diaryl compounds |
GB9406005-0 | 1994-03-25 | ||
PCT/GB1994/001409 WO1995001326A1 (en) | 1993-06-30 | 1994-06-29 | Anti-atherosclerotic diaryl compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08512046A true JPH08512046A (ja) | 1996-12-17 |
JP3894949B2 JP3894949B2 (ja) | 2007-03-22 |
Family
ID=26303144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50335795A Expired - Fee Related JP3894949B2 (ja) | 1993-06-30 | 1994-06-29 | 抗アテローム性動脈硬化症ジアリール化合物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5776951A (ja) |
EP (1) | EP0706508A1 (ja) |
JP (1) | JP3894949B2 (ja) |
AU (1) | AU7006094A (ja) |
CA (1) | CA2166413A1 (ja) |
HU (1) | HUT73813A (ja) |
IL (1) | IL110159A0 (ja) |
WO (1) | WO1995001326A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007506646A (ja) * | 2003-09-26 | 2007-03-22 | 日本たばこ産業株式会社 | レムナントリポ蛋白生成阻害方法 |
JP2010513265A (ja) * | 2006-12-17 | 2010-04-30 | マクテシム・ケミカル・ワークス・リミテツド | 置換されたシアノフェノキシ−ピリミジニルオキシ−フェニルアクリラート誘導体の調製方法 |
JP2013540714A (ja) * | 2010-09-06 | 2013-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | エチン誘導体、医薬組成物及びその使用 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU729415B2 (en) | 1996-07-12 | 2001-02-01 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
US6867203B2 (en) | 1998-12-29 | 2005-03-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6878700B1 (en) * | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6110922A (en) | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6599942B1 (en) | 1999-03-29 | 2003-07-29 | Novartis Ag | Thyromimetic organic compounds |
US6790978B2 (en) * | 1999-03-29 | 2004-09-14 | Novartis Ag | Thyromimetic organic compounds |
ES2437103T3 (es) * | 1999-06-30 | 2014-01-08 | Amgen Inc. | Compuestos para la modulacion de la actividad de PPAR gamma |
US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
AU7353300A (en) * | 1999-09-08 | 2001-04-10 | Guilford Pharmaceuticals Inc. | Non-peptidic cyclophilin binding compounds and their use |
US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
NZ523445A (en) | 2000-06-29 | 2004-10-29 | Abbott Lab | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
DE10059418A1 (de) * | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
CA2430951A1 (en) * | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
JP2004532187A (ja) | 2001-01-25 | 2004-10-21 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 三置換カルボサイクリックサイクロフィリン結合化合物とその用途 |
US7041280B2 (en) | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
DE10258168B4 (de) * | 2002-12-12 | 2005-07-07 | Infineon Technologies Ag | Integrierter DRAM-Halbleiterspeicher und Verfahren zum Betrieb desselben |
NZ541234A (en) | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法 |
ES2377121T3 (es) * | 2003-03-17 | 2012-03-22 | Japan Tobacco Inc. | Composiciones farmacéuticas de inhibidores de CETP |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
BRPI0508098A (pt) | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
KR100927563B1 (ko) | 2004-08-06 | 2009-11-23 | 오쓰까 세이야꾸 가부시키가이샤 | 방향족 화합물 |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
US8008303B2 (en) | 2005-09-16 | 2011-08-30 | Astrazeneca Ab | Biphenyl derivatives and their use in treating hepatitis C |
RU2444362C2 (ru) | 2005-12-05 | 2012-03-10 | Оцука Фармасьютикал Ко., Лтд. | Лекарственное средство |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
EP2061760A1 (en) | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
TW200900072A (en) * | 2007-03-22 | 2009-01-01 | Arete Therapeutics Inc | Soluble epoxide hydrolase inhibitors |
WO2008130514A1 (en) | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
US7858666B2 (en) | 2007-06-08 | 2010-12-28 | Mannkind Corporation | IRE-1α inhibitors |
WO2009048527A1 (en) | 2007-10-10 | 2009-04-16 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
CA2707789A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Phenyl acetic acid derivatives as inflammation modulators |
JP2011507909A (ja) | 2007-12-20 | 2011-03-10 | エンビボ ファーマシューティカルズ インコーポレイテッド | 四置換ベンゼン |
WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2225873A1 (de) * | 1972-05-27 | 1973-12-13 | Bayer Ag | Isocyandiphenylaether |
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
GB8827152D0 (en) * | 1988-11-21 | 1988-12-29 | Wellcome Found | Anti-atherosclerotic diaryl compounds |
US5290814A (en) * | 1988-11-21 | 1994-03-01 | Burroughs Wellcome Co. | Anti-atherosclerotic diaryl compounds |
US5385912A (en) * | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
DE59308508D1 (de) * | 1992-01-29 | 1998-06-10 | Basf Ag | Carbamate und diese enthaltende pflanzenschutzmittel |
-
1994
- 1994-06-29 IL IL11015994A patent/IL110159A0/xx unknown
- 1994-06-29 WO PCT/GB1994/001409 patent/WO1995001326A1/en not_active Application Discontinuation
- 1994-06-29 AU AU70060/94A patent/AU7006094A/en not_active Abandoned
- 1994-06-29 HU HU9501813A patent/HUT73813A/hu unknown
- 1994-06-29 JP JP50335795A patent/JP3894949B2/ja not_active Expired - Fee Related
- 1994-06-29 EP EP94918970A patent/EP0706508A1/en not_active Withdrawn
- 1994-06-29 US US08/564,281 patent/US5776951A/en not_active Expired - Fee Related
- 1994-06-29 CA CA002166413A patent/CA2166413A1/en not_active Abandoned
-
1998
- 1998-02-05 US US09/018,936 patent/US6043284A/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007506646A (ja) * | 2003-09-26 | 2007-03-22 | 日本たばこ産業株式会社 | レムナントリポ蛋白生成阻害方法 |
JP2010513265A (ja) * | 2006-12-17 | 2010-04-30 | マクテシム・ケミカル・ワークス・リミテツド | 置換されたシアノフェノキシ−ピリミジニルオキシ−フェニルアクリラート誘導体の調製方法 |
US8471013B2 (en) | 2006-12-17 | 2013-06-25 | Makhteshim Chemical Works, Ltd. | Process for the preparation of substituted cyanophenoxy-pyrimidinyloxy-phenyl acrylate derivatives |
JP2013540714A (ja) * | 2010-09-06 | 2013-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | エチン誘導体、医薬組成物及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
JP3894949B2 (ja) | 2007-03-22 |
WO1995001326A1 (en) | 1995-01-12 |
IL110159A0 (en) | 1994-10-07 |
AU7006094A (en) | 1995-01-24 |
US5776951A (en) | 1998-07-07 |
CA2166413A1 (en) | 1995-01-12 |
EP0706508A1 (en) | 1996-04-17 |
HUT73813A (en) | 1996-09-30 |
US6043284A (en) | 2000-03-28 |
HU9501813D0 (en) | 1995-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08512046A (ja) | 抗アテローム性動脈硬化症ジアリール化合物 | |
JP4018545B2 (ja) | Fsadのためのnep阻害剤としてのn−フェンプロピルシクロペンチル−置換グルタルアミド誘導体 | |
JP2002537286A (ja) | チオアミド誘導体 | |
JP2000506538A (ja) | メタ―置換フェニレン誘導体 | |
JP2003509410A (ja) | カテプシンインヒビターとしての化合物および薬学的組成物 | |
IL234755A (en) | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | |
EP2755944B1 (en) | Biarylderivatives,their preparation and their therapeutic application | |
KR100417670B1 (ko) | 비시클릭아미드유도체및근이완제로서의이의용도 | |
JP2013503819A (ja) | 治療性アリール−アミド−アリール化合物およびその使用 | |
JP2002512639A (ja) | プロパノールアミン誘導体 | |
JP2003300875A (ja) | インターロイキン12抑制剤 | |
PL209113B1 (pl) | Cykloheksylosulfony, zawierająca je kompozycja farmaceutyczna i zastosowanie związków | |
JPH09512814A (ja) | アミド誘導体およびそれらの治療用途 | |
RU2404966C2 (ru) | Замещенное акриламидное производное и фармацевтическая композиция на его основе | |
JPH07500604A (ja) | 高血圧治療用エチルアラニンアミノジオール化合物 | |
JPH0222059B2 (ja) | ||
JPH05247036A (ja) | チアゾリル置換キノリルメトキシフエニル酢酸誘導体 | |
HU210683B (en) | Process for producing n-benzyl-n1-(phenyl-alkyl)-thiourea derivatives and pharmaceutical compositions containing the same | |
JPH09510718A (ja) | 5ht1dアンタゴニストとしてのビフェニル誘導体 | |
KR100309754B1 (ko) | 벤젠유도체및이를함유하는약제학적조성물 | |
JPH08509491A (ja) | 胃腸疾患の治療に有用なエタノールアミン誘導体 | |
BE1001376A4 (fr) | Derives de l'acide benzoique et leur procede de preparation. | |
TWI335312B (en) | Formamide derivatives for the treatment of diseases | |
AU684778C (en) | Bicyclic amide derivatives and their use as muscle relaxants | |
JPH06500315A (ja) | ベンズアミド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041217 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051005 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060607 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061016 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061213 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |